

ITL BioMedical Launches Safety Sub Culture Unit 2

ITL Health Group (ASX:ITD), is pleased to announce the launch of ITL BioMedical's latest innovative product to support the microbiology laboratory blood culture testing process. The Safety Sub Culture Unit 2 (SCU2) is one of a pipeline of new products to be brought to market in the current financial year.

ITL has sold the original SCU for over eight years, into multiple countries. The SCU2 was designed and created in partnership with laboratory technologists who use these products and is compatible with most manufacturers blood culture reagent bottles.

SCU2 is a safety oriented, needleless device used to transfer positive blood culture samples from the reagent bottle for further testing. SCU2 represents a subculture ancillary product line extension adding to the ITL BioMedical products in this category.

SCU2 is the fifth new product ITL BioMedical has launched as it continues to build its presence in the global Blood Culture Testing market. The Blood Culture Testing market is estimated to be worth US\$3.3b in 2016 and growing to US\$4.8b by 2021⁽¹⁾. The growth is due to an increase in the number of sepsis cases, rapidly ageing population and a growing recognition of the need to test blood samples for the presence of bacteria. There are an estimated 25 million subculture procedures performed annually on a global basis.

Over the last financial year, ITL Health Group has spent over \$4m in research and development across the groups' product lines, resulting in a healthy pipeline of new products that will reach the market through 2018.

Craig Wilson, General Manager of ITL BioMedical commented "The SCU2 product is building on the success of the original SCU product and has been designed in direct response to our customer's requests, initial market feedback has given us considerable confidence."

(1) MarketsandMarkets.com

About ITL BioMedical

ITL BioMedical is a division of ITL Health Group ([ASX:ITD](#)) that sets industry standards for the innovative design and production of biological sampling systems and healthcare devices for human and animal use. The Division's patented medical devices focus on safety and process efficiency for end-users and their blood donors and patients in blood collection centers and healthcare markets worldwide. For more information or inquiries, visit [ITLBioMedical.com](#)

ITL Health Group

ITL is an innovative global medical technology company made up of two divisions; ITL BioMedical and MyHealthTest. ITL holds an IP portfolio of more than 50 patents and sells into 55 countries.

ITL BioMedical creates and manufactures leading edge medical devices for the clinical, blood banking, and laboratory markets and is a growing provider of specialist ancillary products for the blood culture testing market.

MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.



Ranked 16th most Innovative Company by the
AFR Innovative Companies Awards

Australian Securities Exchange

Code: ITD

Ordinary Shares

85,552,339

Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director
Trevor Doolan	Chief Financial Officer & Company Secretary

ITL Contact

Trevor Doolan	Company Secretary
Phone:	+61 3 9088 7991
Email:	infor@itlhealthgroup.com
Address	Unit 1, 63 Wells Road Chelsea Heights, Victoria, 3196

www.itlhealthgroup.com

Media

Walbrook IR	Ben Knowles
Phone:	+61 426 277 760
Email:	ben.knowles@walbrookir.co.au